B8

acids), soybean lecithin (0.2 pts.wt.) and albumen (10 pts.wt.) was stirred, to which was added milk (180 pts.wt.) and stirred for 2 minutes to give milk contg. fats and oils, which was used as fluid diet. Energy was 133 kcal. Protein content was 6.6 g; lipid was 7.7 and sugar was 8.7 g. There was no problem in taste and appearance.

Dwg.0/0

Title Terms: MEDICAL; COMPOSITION; CONTAIN; FAT; OIL; MIX; TRI; GLYCERIDE; USEFUL; ACCUMULATE; DOCOSA; HEXENOIC; ACID; ORGAN
Derwent Class: B05; D13; D16
International Patent Class (Main): A61K-031/23
International Patent Class (Additional): A61K-035/12; A61K-035/80; C12P-007/64; C12R-001-89
File Segment: CPI
Manual Codes (CPI/A-N): B04-B01B; B04-B01C; B14-J01; D03-H01G; D03-H01H; D03-H01J; D03-H01T2; D05-H
Chemical Fragment Codes (M2):
01 H721 H722 H723 J0 J013 J2 J273 M225 M226 M231 M232 M233 M262 M283 M313 M321 M332 M343 M383 M391 M416 M431 M620 M782 M903 M904 P440 P450 Q220 Q233 R90112-M
Specific Compound Numbers: R90112-M
?t 010832478/9

010832478/9
DIALOG(R)File 351:DERWENT WPI

010832478
WPI Acc No: 96-329430/199633
XRAM Acc No: C96-104348
Liposomes for drug delivery for treating ischaemic heart diseases - contains membrane forming lipid comprising phosphatidyl- choline contg. docosa-hexaenoic acid
Patent Assignee: SAGAMI CHEM RES CENTRE (SAGA)
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
JP 8151334	A	19960611	JP 94291329	A	19941125	A61K-047/24	199633 B

Priority Applications (No Type Date): JP 94291329 A 19941125
Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
JP 8151334	A		6			

Abstract (Basic): JP 8151334 A

Liposome contains as membrane-forming lipid comprising a phosphatidylcholine (PC) in which docosahexaenoic acid (DHA) comprises at least 10% of fatty acids.

Pref. phosphatidylcholine is isolated from the skin of cuttlefish and the liposome contg. ascorbic acid ester of DHA (DHA-As).

DHA pref. comprises at least 25% of the fatty acids forming the phospholipid. PC is pref. isolated from cuttlefish (sPC) by extn. with

a solvent (e.g. CHCl3 or Et2O) and subsequent adsorption chromatography and ion exchange chromatography. The membrane-forming lipid may contain cholesterol and/or charged lipid (e.g. phosphatidyl ethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, phosphatic acid, stearylamine or fatty acid). The membrane stabiliser is antifreeze agent or antioxidant sterol (e.g. cholesterol or cholestanol), sugar, glycolipid, glycerol, polyethylene glycol, tocopherol or ascorbic acid which may be added in amt. of up to 1 mole for 1 mole PC.

USE/ADVANTAGE - The liposome may be used in delivery of lipophilic and hydrophobic drugs, partic. DHA-As which is useful as a calcium antagonist (WO94/20092) used in treatment of ischaemic heart diseases e.g. angina pectoris, myocardial infarction or hypertension. The liposome is highly stable in the living body. High content of DHA-As can be maintained in the liposome so that the release of DHA-As in the living body can be controlled.

Dwg.0/5

Title Terms: DRUG; DELIVER; TREAT; ISCHAEMIC; HEART; DISEASE; CONTAIN; MEMBRANE; FORMING; LIPID; COMPRISE; PHOSPHATIDYL; CHOLINE; CONTAIN; DOCOSA; HEXA; ENOIC; ACID

Derwent Class: B05

International Patent Class (Main): A61K-047/24

International Patent Class (Additional): A61K-009/127; A61K-031/375

File Segment: CPI

Manual Codes (CPI/A-N): B01-D02; B03-F; B03-H; B04-B01B; B04-C03C; B04-N05; B05-B01P

Chemical Fragment Codes (M2):

01 F012 F013 F014 F015 F113 H4 H401 H402 H421 H481 H482 H7 H723 H8 J0 J011 J2 J221 J271 J5 J522 L660 L9 L942 L960 M226 M231 M262 M281 M312 M321 M332 M343 M373 M391 M413 M431 M510 M521 M530 M540 M782 M903 M904 Q620 R033 V0 V330 9633-11501-M

02 H7 H723 J0 J011 J1 J171 M226 M231 M262 M281 M320 M416 M431 M782 M903 M904 Q620 R033 R04471-M

03 B415 B701 B713 B720 B815 B831 H1 H100 H181 H721 H722 J0 J013 J1 J171 J2 J272 M220 M224 M225 M226 M231 M232 M233 M262 M282 M312 M313 M321 M332 M342 M343 M349 M381 M383 M391 M411 M431 M510 M520 M530 M540 M620 M782 M903 M904 Q620 R033 R17037-M

04 B415 B701 B713 B720 B815 B831 H1 H181 H721 H722 J0 J012 J2 J272 K0 L7 L722 M210 M211 M225 M231 M262 M273 M282 M283 M312 M313 M321 M332 M342 M343 M383 M392 M411 M431 M510 M520 M530 M540 M620 M782 M903 M904 M910 Q620 R033 V0 V771 R01833-M

05 B415 B701 B713 B720 B815 B831 H100 H181 H721 H722 J0 J012 J2 J272 M225 M226 M231 M262 M282 M312 M313 M321 M332 M342 M343 M383 M392 M411 M431 M510 M520 M530 M540 M620 M782 M903 M904 Q620 R033 V0 V771 R08754-M

Derwent Registry Numbers: 1833-U

Specific Compound Numbers: R04471-M; R17037-M; R01833-M; R08754-M

Generic Compound Numbers: 9633-11501-M

?t 010257634/9

010257634/9

File 347:JAPIO Oct 1976-2000/Jul(UPDATED 001114)
(c) 2000 JPO & JAPIO

Set	Items	Description
?S PN=JP 8027010		
S1	1	PN=JP 8027010

?T 1/9/1

1/9/1
DIALOG(R)File 347:JAPIO

05071510
CARCINOSTATIC IMMUNOTHERAPEUTIC AGENT

PUB. NO.: 08-027010 [*JP 8027010* A]
PUBLISHED: January 30, 1996 (19960130)
INVENTOR(s): YAMAMOTO TETSUO
IWATANI TSUNAICHI
OHASHI KAZUTOMO
YAZAWA KAZUYOSHI
APPLICANT(s): NICHINICHI SEIYAKU KK [000000] (A Japanese Company or Corporation), JP (Japan)
SAGAMI CHEM RES CENTER [351929] (A Japanese Company or Corporation), JP (Japan)
APPL. NO.: 06-188756 [JP 94188756]
FILED: July 19, 1994 (19940719)
INTL CLASS: [6] A61K-035/74; A61K-031/20
JAPIO CLASS: 14.4 (ORGANIC CHEMISTRY -- Medicine); 14.5 (ORGANIC CHEMISTRY -- Microorganism Industry)
JAPIO KEYWORD:R051 (PHARMACEUTICALS -- Anti-cancer Agents)

ABSTRACT

PURPOSE: To obtain an carcinostatic immunotherapeutic agent by combining a bacterium Enterococcus faecalis having excellent immunopotentiating actions with docosahexaenoic acid and enhancing the carcinostatic actions thereof.

CONSTITUTION: This therapeutic agent or improving agent is obtained by combining a bacterium Enterococcus faecalis which is one of indigenous bacteria, belonging to steptopcocci and present in the intestines with docosahexaenoic acid and effective against various cancers such as mammary cancer or the carcinoma of the colon. The bacterium Enterococcus faecalis is preferably produced by using NF-1011 strain (FERM P-12564) in aspects of especially high carcinostatic activities. The bacterium Enterococcus faecalis is preferred from the viewpoint of stronger tumor necrosis factor productivity of the dead microbial cell thereof. A fish oil extracted from a blueback fish such as a sardine, a mackerel, a horse mackerel, a salmon or a saury, a fish oil derived from orbital fats of a large-sized marine fish such as a tuna or a bonito and an oil and a fat, etc., derived from a microorganism or a seaweed are cited as the docosahexaenoic acid.